Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
REVENUES:
Net pharmaceutical product sales	$ 535,744	$ 504,600
Devices revenues	122,652	130,166
Service and other revenues	50,123	55,867
TOTAL REVENUES	708,519	690,633
COSTS AND EXPENSES:
Cost of revenues	285,926	364,820
Selling, general and administrative	236,382	254,454
Research and development	41,569	88,688
Litigation-related and other contingencies	68,232	0
Asset impairment charges	1,100	40,000
Acquisition-related and integration items, net	1,318	3,749
OPERATING INCOME (LOSS)	73,992	(61,078)
INTEREST EXPENSE, NET	44,303	46,896
NET LOSS ON EXTINGUISHMENT OF DEBT	11,312	5,426
OTHER (INCOME) EXPENSE, NET	(18,168)	451
INCOME (LOSS) BEFORE INCOME TAX	36,545	(113,851)
INCOME TAX	9,942	(39,326)
CONSOLIDATED NET INCOME (LOSS)	26,603	(74,525)
Less: Net income attributable to noncontrolling interests	11,254	12,820
NET INCOME (LOSS) ATTRIBUTABLE TO ENDO HEALTH SOLUTIONS INC.	$ 15,349	$ (87,345)
NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO ENDO HEALTH SOLUTIONS INC.
Basic (usd per share)	$ 0.14	$ (0.75)
Diluted (usd per share)	$ 0.14	$ (0.75)
WEIGHTED AVERAGE SHARES:
Basic (shares)	111,216	117,052
Diluted (shares)	113,189	117,052